HY-133

HY-133 is a recombinant bacteriophage endolysin with bactericidal activity against Staphylococcus aureus, including methicillin-resistant strains (MRSA). It employs a chimeric design combining the CHAP domain from phage K with lysostaphin's cell wall-binding domain. The drug acts by targeting peptidoglycan in bacterial cell walls, rapidly destroying S. aureus cells within minutes while preserving the normal nasal microbiota. It is formulated as a hydrogel for nasal administration and is being developed primarily for decolonization of S. aureus in the nasal cavity to prevent infections during hospital stays and surgeries.

Other names

recombinant chimeric bacteriophage endolysin HY-133